Coya Therapeutics, Inc. (COYA)
Largest Insider Buys in Sector
COYA Stock Price History Chart
COYA Stock Performance
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in …
Insider Activity of Coya Therapeutics, Inc.
Over the last 12 months, insiders at Coya Therapeutics, Inc. have bought $106,393 and sold $0 worth of Coya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Coya Therapeutics, Inc. have bought $55,007 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Swaminathan Arun (Chief Executive Officer) — $73,486. SNYDER DAVID S (Chief Financial Officer) — $25,869. Grossman Fred (Chief Medical Officer) — $19,973.
The last purchase of 1,800 shares for transaction amount of $12,934 was made by SNYDER DAVID S (Chief Financial Officer) on 2024‑11‑14.
List of Insider Buy and Sell Transactions, Coya Therapeutics, Inc.
| 2024-11-14 | Chief Financial Officer | 1,800 0.0126% | $7.19 | $12,934 | -12.05% | |||
| 2024-11-13 | Chief Executive Officer | 5,000 0.0335% | $7.36 | $36,797 | -15.68% | |||
| 2024-11-11 | Chief Executive Officer | 5,000 0.0336% | $7.34 | $36,689 | -16.51% | |||
| 2024-11-11 | Chief Medical Officer | 2,710 0.0183% | $7.37 | $19,973 | -16.51% | |||
| 2023-08-22 | director | 1,000 0.0104% | $3.62 | $3,620 | +94.80% | |||
| 2023-01-03 | director | 10,000 – | $0 | $0 | -1.94% | |||
| 2023-01-03 | director | 10,000 – | $0 | $0 | -1.94% | |||
| 2023-01-03 | Chief Medical Officer | 10,000 – | $0 | $0 | -1.94% | |||
| 2023-01-03 | director | 10,000 – | $0 | $0 | -1.94% | |||
| 2023-01-03 | Chief Executive Officer | 10,000 – | $0 | $0 | -1.94% | |||
| 2023-01-03 | Chief Financial Officer | 7,000 – | $0 | $0 | -1.94% | |||
| 2023-01-03 | director | 2,000 – | $0 | $0 | -1.94% |
Institutional Investor Ownership
| The Vanguard Group | $8.41M | 5.57 | 847,490 | +772.33% | +$7.44M | <0.0001 | |
| Aigh Capital Management Llc | $6.44M | 4.27 | 649,427 | -37.07% | -$3.79M | 3.68 | |
| Geode Capital Management | $1.25M | 0.83 | 125,996 | +36.26% | +$332,685.45 | <0.0001 | |
| Raymond James Associates | $1.09M | 0.72 | 110,095 | New | +$1.09M | <0.01 | |
| Cm Management Llc | $992,000.00 | 0.66 | 100,000 | 0% | +$0 | 0.02 |